1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > RORgamma Modulators 2016: A comparative analysis of the landscape of RORgamma antagonists and agonists

RORgamma Modulators 2016: A comparative analysis of the landscape of RORgamma antagonists and agonists


Retinoic acid-related orphan nuclear receptor gamma (RORgamma) is a hot, but „difficult-to-drug“ target. More than 30 companies are active in drug discovery and development. Technology companies with expertise in discovery of drugs targeting nuclear hormone receptors are preferred partners of Big Pharma and Biotech companies if they have identified novel scaffolds of RORgamma antagonists. More than ten such technology-pharma partnerships have been founded and already lead to first successes. Three RORgamma antagonists (inverse agonists) are already in clinical development and more to follow in 2016 and thereafter. 


The report explains the scientific rationale for discovering antagonists of RORgamma for treatment of autoimmune and inflammatory diseases, but also of agonists of RORgamma for treatment of cancer. Clinical as well as non-clinical data for target validation of RORgamma are provided. Lead and up-side indications for development including the key product profile are discussed. Potential safety concers for novel RORgamma modulators were identified. Drug discovery approaches of technology and pharmaceutical companies are shown regarding strategies in partnering as well as in technologies applied for structure-based drug discovery. Based on the experience in the past, estimates of the required time from start of a discovery program of RORgamma modulators until entry into human studies are calculated. The competitive landscape of RORgamma modulator development and discovery projects is analyzed and the profiles of companies elaborated, separately for unpartnered technology or pharmaceutical companies and for partnerships between technology and pharmaceutical companies.


The report provides an understanding of:



  • The target RORgamma

  • Clinical and non-clinical target validation

  • Clinical lead and up-side indications

  • Drug discovery strategies and technologies

  • Commercial value of drug discovery collaborations

  • R&D timelines from start of screening to first-in-human studies

  • Competitive landscape of RORgamma antagonists

  • Agonists of RORgamma for cancer

  • Profiles of unpartnered technology companies and lead projects

  • R&D Partnerships and their discovery approaches and lead molecules

  • Unpartnered pharmaceutical companies and their programs


Table Of Contents

RORgamma Modulators 2016: A comparative analysis of the landscape of RORgamma antagonists and agonists


Table of Contents


1) Introduction


2) Executive Summary


3) Target Background


4) Target validation


• Clinical Success of Anti-IL17 Antibodies


• Non-Clinical Target Validation


• Clinical Lead Indication for RORgamma Antagonists


• Target-related Potential Safety Concerns


5) Drug Discover Approaches and Technologies


• Drug Discovery Collaboration


• Commercial Value of RORgamma Modulator Drug Discovery Collaborations


• RandD Timelines for Discovery of RORgamma Antagonists in Partnership Programs


• Strategies for the Discovery of Nuclear Receptor Ligands


6) Competitive Landscape of RORgamma Modulators


• RORgamma Antagonists for Inflammatory and Autoimmune Diseases


• Agonists of RORgamma for Cancer


7) Corporate Stakeholders


• Unpartnered Technology Companies


• Partnerships


• Unpartnered Pharmaceutical Companies


8) References?


RORgamma Modulators 2016: A comparative analysis of the landscape of RORgamma antagonists and agonists



Tables in the report


Table 1: Disease Models Used for Non-Clinical Studies of RORgamma Antagonists

Table 2: Overview of Non-Clinical Studies of RORgamma Antagonists in Psoriasis Models

Table 3: Overview of Non-Clinical Studies of RORgamma Antagonists in Multiple Sclerosis Models

Table 4: Overview of Non-Clinical Studies of RORgamma Antagonists in Arthritis Models

Table 5: Overview of Non-Clinical Studies of RORgamma Antagonists in Inflammatory Bowel Disease and Ulcerative Colitis Models

Table 6: Overview of Non-Clinical Studies of RORgamma Antagonists in Systemic Lupus Erythematosus Models

Table 6: Overview of Partnership Agreements for RORgamma Modulators

Table 7: Special Collaborations for Discovery of RORgamma Antagonists

Table 8: Financial Terms of Partnership Agreements for RORgamma Modulators

Table 9: Randamp;D Timeline for Discovery of RORgamma Antagonists in Partnership Programs

Table 10: Technologies for Discovery of RORgamma Antagonists

Table 11: RORgamma(T) Antagonists / Inverse Agonists in Clinical Development

Table 12: RORgamma(T) Antagonists / Inverse Agonists in pre-IND Studies

Table 13: RORgamma(T) Antagonists / Inverse Agonists in Preclinical Randamp;D

Table 14: RORgamma(T) Antagonists / Inverse Agonists Discovery Programs

Table 15: RORgamma Agonists Discovery andamp; Development Programs

Table 16: Technology and Pharma Companies with RORgamma Modulator Randamp;D

RORgamma Modulators 2016: A comparative analysis of the landscape of RORgamma antagonists and agonists



Companies mentioned in the report


4SC Discovery

Advinus Therapeutics

Amgen

Argenta

Arrien Pharmaceuticals

AstraZeneca

Aurigene Discovery Technologies

Biogen

Boehringer Ingelheim

Brickell Biotech

Bristol-Myers Squibb

Celgene

Daiichi Sankyo

Exelixis

Genfit

GlaxoSmithKline

Glenmark Pharmaceuticals

Innovimmune Biotherapeutics

Janssen Biotech

Japan Tobacco

Karo Bio

Lycera

Merck

Nuevolution

ORCA Pharmaceuticals

Orphagen Pharmaceuticals

Pfizer

Phenex Pharmaceuticals

Piramal (andamp; Krish Biotech)

Roche

Takeda Pharmaceutical Co.

Teijin Pharma

Tempero Pharmaceuticals

Visionary Pharmaceuticals

Vitae Pharmaceuticals

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Psoriatic Arthritis - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Psoriatic Arthritis - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • December 2016
  • by GlobalData

PharmaPoint: Psoriatic Arthritis - Global Drug Forecast and Market Analysis to 2025 Summary Psoriatic arthritis (PsA) is a chronic immune-mediated arthritis typically affecting the large joints, especially ...

Human Microbiome Market by Indication, Application, Product, Product Research, Technology Research - Global Forecast to 2025

Human Microbiome Market by Indication, Application, Product, Product Research, Technology Research - Global Forecast to 2025

  • $ 5650
  • Industry report
  • March 2017
  • by MarketsandMarkets

The global human microbiome market is estimated to reach USD 899.1 million by 2025, growing at a CAGR of 21.1% during the forecast period (2022–2025) Factors such as increased focus on human microbiome ...

Ankylosing spondylitis (AS)- Market Insights, Epidemiology and Market Forecast-2023

Ankylosing spondylitis (AS)- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • January 2017
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Ankylosing spondylitis (AS) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.